A Selection of Recent Papers

Proteomic Analysis of Archival Breast Cancer Serum. B.A. ZEIDAN, R.I. CUTRESS, N. MURRAY, G. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (Southampton; Gosport; London; Portsmouth, UK)

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, X. ZHOU (Chicago, IL, USA; Guangzhou, China)

Increased levels of macrophage-secreted Cathepsin S during prostate cancer progression in TRAMP mice and patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (Umeå, Sweden)

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J. SANDERS, M.A. KAYANI, W.G. JIANG (Cardiff, Wales, UK; Islamabad, Pakistan)

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L. P. PARKER, D.D. TAYLOR, S. KERSTERSON, C. GERCEL-TAYLOR (Louisville KY, USA)

Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP (Greenville; Chapel Hill, NC, USA)

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes caused by BPDE. M. REIT-ER, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (Munich, Germany)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (Columbus, OH, USA; Ferrara; Meldola, Italy)

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES, W.G. JIANG (Cardiff, UK)

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANTOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (Turin; Milan, Italy)

Gene Expression Analysis of HCT116 Colon Tumor Derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (Tucson, AZ; Redwood City, CA, USA; Haifa, Israel)

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (Mainz, Germany)
Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios  
   International Institute of Anticancer Research (IIAR)  
   Editorial Office of ANTICANCER RESEARCH,  
   IN VIVO, CANCER GENOMICS and PROTEOMICS.  
   1st km Kapandritiou-Kalamou Road  
   P.O. Box 22, GR-19014 Kapandriti, Attiki  
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandriotou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389. e-mail: journals@iiar-anticancer.org
For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iiar-anticancer.org

Selection of Recent Articles


Transgenic Mice Expressing Constitutively Active Akt in Oral Epithelium Validate Klf4 as a Potential Biomarker of Head and Neck Squamous Cell Carcinoma. M. MORAL, C. SEGRELLES, A.B. MARTÍNEZ-CRUZ, C. LORZ, et al. (Madrid, Spain; Smithville, TX, USA)

Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients. M. FRÉMONT, K. METZGER, H. RODY, J. HULSTAERT, K. DE MEIRLEIR (Zellik; Brussels; Vilvoorde, Belgium)

A Bioluminescent Orthotopic Mouse Model of Human Osteosarcoma that Allows Sensitive and Rapid Evaluation of New Therapeutic Agents In Vivo. K.E. COMSTOCK, C.L. HALL, S. Daignault, S.A. Mandlebaum, C. YU, E.T. KELLER (Ann Arbor, MI, USA)

Obesity Impairs Wound Healing in Ovariectomized Female Mice. V.B. HOLCOMB, V.A. KECK, J.C. BARRETT, J. HONG, S.K. LIBUTTI, N.P. NUÑEZ (Austin, TX; Bethesda, MD; Cambridge, MA; Bronx, NY, USA)


Inhibiting Platelet Derived Growth Factor Beta (PDGFR-B) Decreases Ewing’s Sarcoma Growth and Metastasis in a Novel Orthotopic Human Xenograft Model. Y.X. WANG, D. MANDAL, S. WANG, D. HUGHES, R.E. POLLOCK, D. LEV, E. KLEINERMAN, A. HAYES-JORDAN (Houston, TX, Kingston, RI, USA)

Ethyl-eicosapentaenoic Acid Reduces Liver Lipids and Lowers Plasma Levels of Lipids in Mice fed a High-fat Diet. N. NEMOTO, S. SASSA, S. SUZUKI, H. KIKUCHI, H. OKABE, S. SAKAMOTO (Chiba; Tokyo, Japan)

Distribution of [3H] Corticosterone in Urine, Feces and Blood of Male Sprague-Dawley Rats After Tail Vein and Jugular Vein Injections. K.S.P. ABELSON, S.S. FARD, N. NYMAN, R. GOLDKUHL, J. HAU (Uppsala, Sweden; Copenhagen, Denmark)

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increase Adenoma and Flat ACF Number in the Intestine of Min/+ Mice. C. RÖNNINGBORG, T. HUS-Y, H. GLATT, J.E. PAULSEN, J. ALEXANDER (Oslo, Norway; Nuthetal, Germany)

Ocular Toxicity Caused by Paclitaxel in Neonatal Sprague-Dawley Rats. M. KUWATA, K. YOSHIZAWA, M. MATSUMURA, A. TSUBURA (Osaka, Japan)
Vitamin D-24-Hydroxylase in Benign and Malignant Breast Tissue and Cell Lines. D. FISCHER, S. BECKER, T. CORDES, B. BÜCKER, K. DIEDRICH, M. FRIEDRICH, D. SALEHIN, M. THILL (Lübeck; Krefeld, Germany) ........................................... 3641

Cross-talk between Vitamin D Receptor (VDR)- and Peroxisome Proliferator-activated Receptor (PPAR)-signaling in Melanoma Cells. P. SERTZNIG, T. DUNLOP, M. SEIFERT, W. TILGEN, J. REICHRATH (Homburg/Saar, Germany; Kuopio, Finland) .............................................................. 3647

Expression of 25-Hydroxyvitamin D-1α-Hydroxylase (1αOHase, CYP27B1) Splice Variants in HaCaT Keratinocytes and Other Skin Cells: Modulation by Culture Conditions and UV-B Treatment In Vitro. M. SEIFERT, W. TILGEN, J. REICHRATH (Homburg, Germany) .................................................................................................................. 3659

Reduced Serum 25-Hydroxyvitamin D Levels in Stage IV Melanoma Patients. B. NÜRNBERG, S. GRÄBER, B. GÄRTNER, J. GEISEL, C. PFÖHLER, D. SCHADENDORF, W. TILGEN, J. REICHRATH (Homburg; Essen, Germany) ........................................................................................................................................ 3669

* Review: How to Optimize Vitamin D Supplementation to Prevent Cancer, Based on Cellular Adaptation and Hydroxylase Enzymology. R. VIETH (Toronto, ON, Canada) ........................................................................................................................................ 3675

Part B

Preface: Vitamin D, Calcium, and Cancer. H.S. CROSS, M. PETERLIK (Vienna, Austria) .................................................. 3685

* Review: Calcium, Vitamin D and Cancer. M. PETERLIK, W.B. GRANT, H.S. CROSS (Vienna, Austria; San Francisco, CA, USA) ......................................................................................................................... 3687

* Review: Epidemiology of Vitamin D Insufficiency and Cancer Mortality. S. PILZ, A. TOMASCHITZ, B. OBERMAYER-PIETSCH, H. DOBNIG, T.R. PIEBER (Graz, Austria) ...................................................................................................................... 3699


The Dependency of Vitamin D Status on Body Mass Index, Gender, Age and Season. Z. LAGUNOVA, A.C. POROJNICU, F. LINDBERG, S. HEXEBERG, J. MOAN (Oslo, Norway) ......................................................................................................................... 3713

Mutual Associations between Malignancy, Age, Gender, and Subsite Incidence of Colorectal Cancer. W. BROZEK, S. KRIWANEK, E. BONNER, M. PETERLIK, H.S. CROSS (Vienna, Austria) ......................................................................................................................... 3721

Parallel Elevation of Colonic 1,25-Dihydroxyvitamin D3 Levels and Apoptosis in Female Mice on a Calcium-deficient Diet. T. NITTKE, E. KALLAY, T. MANHARDT, H.S. CROSS (Vienna, Austria) ......................................................................................................................... 3727

* Reviews (pages 3471, 3485, 3495, 3501, 3511, 3597, 3675, 3687, 3699, 3705)
Air Pollution in Relation to U.S. Cancer Mortality Rates: An Ecological Study; Likely Role of Carbonaceous Aerosols and Polycyclic Aromatic Hydrocarbons. W.B. GRANT (San Francisco, CA, USA) .......................................................... 3537

Evaluation of 19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D₃ as a Therapeutic Agent for Androgen-dependent Prostate Cancer. J.N. FLANAGAN, S. ZHENG, K.-C. CHIANG, A. KITTAKA, T. SAKAKI, S. NAKABAYASHI, X. ZHAO, R.A. SPANJAARD, K.S. PERSONS, J.S. MATHIEU, M.F. HOLICK, T.C. CHEN (Boston, MA, USA; Kaohsiung, Taiwan, ROC; Kanagawa; Toyama, Japan; Stockholm, Sweden) .......................................................... 3547

Regulation of Steroid Receptor Expression by 1α-Hydroxyvitamin D₅ in Hormone-responsive Breast Cancer Cells. E.A. HUSSAIN-HAKIMJEE, R.G. MEHTA (Chicago, IL, USA) .................................................................................................................. 3555


Synthesis of All Possible A-ring Diastereomers at the 1- and 3-Positions of 1α,25-Dihydroxy-2β-(3-hydroxypropoxy)vitamin D₃ (ED-71) Using C₂-Symmetrical Epoxide as a Common Starting Material. N. KUBODERA, S. HATAKEYAMA (Tokyo; Nagasaki, Japan) .................................................................................................................. 3571

Antiproliferative and Calcemic Actions of Trans-Decalin CD-Ring Analogs of 1,25-Dihydroxyvitamin D₃. G. EELEN, L. VERLINDEN, J. LAUREYS, S. MARCELIS, P. DE CLERCQ, C. MATHIEU, R. BOUILLON, A. VERSTUYF (Leuven; Gent, Belgium) .................................................................................................................. 3579

Microarray Analysis of MCF-7 Breast Cancer Cells Treated with 1,25 Dihydroxyvitamin D₃ or a 17-Methyl-D-ring Analog. E. VANORBEEK, G. EELEN, L. VERLINDEN, K. MARCHAL, K. ENGELEN, B. DE MOOR, I. BEULLENS, S. MARCELIS, P. DE CLERCQ, R. BOUILLON, A. VERSTUYF (Leuven; Heverlee; Gent, Belgium) .................................................................................................................. 3585

Fish Oil Enhances the Antiproliferative Effect of 1α,25-Dihydroxyvitamin D₃ on Liver Cancer Cells. K.-C. CHIANG, K.S. PERSONS, N.W. ISTFAN, M.F. HOLICK, T.C. CHEN (Kaohsiung, Taiwan, ROC; Boston, MA, USA) .................................................................................................................. 3591

* Review: Current Impediments to Acceptance of the Ultraviolet-B-Vitamin D-Cancer Hypothesis. W.B. GRANT, B.J. BOUCHER (San Francisco, CA, USA; London, UK) .................................................................................................................. 3597

A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. S. SRINIVAS, D. FELDMAN (Stanford, CA, USA) .................................................................................................................. 3605


Prostaglandin Metabolizing Enzymes in Correlation with Vitamin D Receptor in Benign and Malignant Breast Cell Lines. M. THILL, D. FISCHER, S. BECKER, T. CORDES, C. DITTMER, K. DIEDRICH, D. SALEHIN, M. FRIEDRICH (Lübeck; Krefeld, Germany) .................................................................................................................. 3619


Contents continued on the preceding page